Business
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in
About this update from Lyell Immunopharma, Inc.
[{"type":"text","content":"Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, is presenting preclinical data at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on its product candidates and new genetic and epigenetic reprogramming technologies. This includes new preclinical research on the potential to generate more potent T cells to provide durable anti-tumor functions against certain aggressive solid tumor cancers. “Our SITC presentations showcase compelling preclinical data underlying our lead TIL product candidate, LYL845, as well as the exciting progress Lyell’s research team is making to advance our understanding of how to counter T-cell exhaustion and generate T cells with properties of durable stemness,” said Gary Lee, Ph.D., chief scientific officer at Lyell. “We are applying this research to grow our pipeline by creating new stackable reprogramming technologies as we continue to work toward our mission of developing adoptive T-cell therapies that deliver consistent, reliable and durable responses in solid tumors.” Preclinical Data on LYL845 Two presentations on Friday, Nov. 11 highlight preclinical data on LYL845, Lyell’s tumor-infiltrating lymphocyte (TIL) product candidate being evaluated for safety, tolerability and anti-tumor activity in a first-in-human Phase 1 clinical trial (NCT05573035). (Abstract Nos. 370 and 340). The first presentation, titled “The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity,” showcases the ability of Epi-R technology to successfully expand TIL across three tumor types as compared to the standard (control) process. In this study, expanding TIL with Epi-R technology resulted in 100 percent success rate vs. 70 percent with control, including tumor samples collected from checkpoint inhibitor experienced melanoma patients. The study also includes colorectal tumor samples which have been considered more chal...